EHA 2017 | Clonal evolution – an important factor in treating CLL
Philip Thompson
• 22 Jun 2017
Philip Thompson, MD, from The University of Texas MD Anderson Center, Houston, TX explains the importance of detecting subclonal genetic mutations such as TP53 in patients with chronic lymphocytic leukemia (CLL), noting that often, the mutant cells in these patients become resistant to chemotherapy and therefore survive, which results in patients undergoing relapse. As there are now drugs that act in a TP53-dependent manner, such as ibrutinib and venetoclax, he states that detection of these mutations is vital towards targeting CLL patients for effective therapy. This interview was filmed at the European Hematology Association (EHA) 2017 Annual Congress in Madrid, Spain.
